JP MORGAN/CALL/VERTEX PHARMACEUTICALS/460/0.1/17.01.25 | Market Closed - Börse Stuttgart 04:46:42 2024-07-01 EDT | ||
| 4.99 EUR | -4.59% |
|
| Current month | -4.59% | ||
| 1 month | +25.38% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-01 | 4.99 | -4.59% |
| 24-06-28 | 5.23 | -1.88% |
| 24-06-27 | 5.33 | -1.66% |
| 24-06-25 | 5.42 | +5.45% |
| 24-06-24 | 5.14 | -3.93% |
Delayed Quote Börse Stuttgart
Last update July 01, 2024 at 04:46 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JB95ZA |
| ISIN | DE000JB95ZA1 |
| Date issued | 2023-12-21 |
| Strike | 460 $ |
| Maturity | 2025-01-17 (200 Days) |
| Parity | 10 : 1 |
| Emission price | 3.06 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.36 € |
|---|---|
| Lowest since issue | 2.21 € |
| Spread | 0.2 € |
| Spread % | 3.80% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
471.2
USD
Average target price
468.3
USD
Spread / Average Target
-0.63%
- Stock Market
- Warrants
- Warrant
